Compare GL & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GL | JAZZ |
|---|---|---|
| Founded | 1900 | 2003 |
| Country | United States | Ireland |
| Employees | 3732 | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 10.4B |
| IPO Year | N/A | 2007 |
| Metric | GL | JAZZ |
|---|---|---|
| Price | $138.82 | $179.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $166.18 | ★ $215.92 |
| AVG Volume (30 Days) | 403.3K | ★ 974.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $9.60 | $6.17 |
| Revenue Next Year | $5.54 | $7.66 |
| P/E Ratio | $10.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $109.38 | $95.49 |
| 52 Week High | $152.71 | $198.00 |
| Indicator | GL | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 50.46 |
| Support Level | $135.08 | $176.67 |
| Resistance Level | $143.04 | $182.99 |
| Average True Range (ATR) | 2.96 | 6.39 |
| MACD | -0.78 | -0.90 |
| Stochastic Oscillator | 5.26 | 28.45 |
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.